How has Revolution Medicines, Inc.'s other long-term liabilities changed year-over-year?

Revolution Medicines, Inc.'s other long-term liabilities increased by 63.3% year-over-year, from $3.47M to $5.66M.

Revolution Medicines, Inc. RVMD Other long-term liabilities

Other long-term liabilities at other companies

Exxon MobilXOM

-$357.5M+16.5%

RobloxRBLX

$95M+69.2%

AmgenAMGN

$71M+1.4%

Invesco Mortgage CapitalIVR

$1.79M+26.2%

Phillips 66PSX

$1.02B-9.5%

Ladder CapitalLADR

$45.1M-0.7%

Other financials

Income statement

See full

Revenue-—

Operating income-$445.2M-84.9%

Net income-$453.8M-113%

EPS (diluted)-$2.29-103%

Balance sheet

See full

Cash & equivalents$440.9M+32.2%

Total debt$156.6M+16.6%

Total equity$1.5B-27.8%

Total assets$2.3B-4.7%

Cash flow

See full

Operating cash flow-$354.2M-82.2%

CapEx$1.5M-52.9%

Free cash flow-$355.7M-79.9%

Valuation

See full

Market cap$34.65B+193%

Enterprise value$34.37B+198%

Profitability

See full

Operating margin-88,031.9%-89,488pp

Net margin-76,423.3%-77,733pp

Returns & leverage

See full

Return on equity-76.7%-923pp

Debt / equity0.1×0.0×

Current ratio6.8×-6.7×

Where this comes from

Reported directly by Revolution Medicines, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities.

The official record: Revolution Medicines, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Revolution Medicines, Inc.'s other long-term liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Revolution Medicines, Inc.'s other long-term liabilities?: Revolution Medicines, Inc. (RVMD) reported other long-term liabilities of $5.66M in Q1 2026.
How has Revolution Medicines, Inc.'s other long-term liabilities changed year-over-year?: Revolution Medicines, Inc.'s other long-term liabilities increased by 63.3% year-over-year, from $3.47M to $5.66M.